Analysis of HLA expression in human tumor tissues

Cancer Immunology, Immunotherapy

Volumn 52, Issue 1, 2003, Pages 1-9

  Cabrera, Teresa ^a   López Nevot, Miguel Angel ^a   Gaforio, Jose Juan ^b   Ruiz Cabello, Francisco ^a   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

HLA; Human tumor; Immune escape; LOH; MHC; Microdissection

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER CELL; CANCER GROWTH; CANCER INVASION; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN TISSUE; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

EID: 0037270582     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0332-0     Document Type: Review

References (39)

1. Bai A, Forman J (1997) The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol 159:2139
2. Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta 2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520
3. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for beta 2-microglobulin mutation in mismatch repair - defective colorectal carcinomas. Curr Biol 6:1695
4. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-Cabello F, Garrido F, Stern PL (2000) Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55:401
5. Browning MJ, Krausa P, Rowan A, Hill AB, Bicknell DC, Bodmer JG, Bodmer WF (1993) Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy. J Immunother 14:163
6. Cabrera T, Collado A, Fernandez MA, Ferron A, Sancho J, Ruiz-Cabello F, Garrido F (1998) High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 52:114
7. Cabrera T, Fernandez MA, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50:127
8. Cabrera T, Salinero J, Fernandez MA, Garrido A, Esquivias J, Garrido F (2000) High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol 61:499
9. de Nooij-van Dalen AG, van Buuren-van Seggelen VH, Lohman PH, Giphart-Gassler M (1998) Chromosome loss with concomitant duplication and recombination both contribute most to loss of heterozygosity in vitro. Genes Chromosomes Cancer 21:30
10. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den Tweel J, de Weger R, Tilanus M (1999) HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 54:235
11. Feenstra M, Verdaasdonk M, van der Zwan AW, de Weger R, Slootweg P, Tilanus M (2000) Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest 80:405
12. Fernandez MA, Ruiz-Cabello F, Oliva MR, Cabrera T, Jimenez P, Lopez Nevot MA, Garrido F (2000) Beta 2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. Int J Clin Lab Res 30:87
13. Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487
14. Festenstein H, Garrido F (1986) MHC antigens and malignancy. Nature 322:502
15. Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117
16. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89
17. Garrido F, Cabrera T, Accolla RS, Bensa JC, Bodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades C, Salvaedneschi L, Stern PL, Uchanska-Ziegler B (1997) HLA and cancer. In: Charron D (ed) Genetic diversity of HLA. Functional and medical implications. EDK, Paris, 1:445
18. Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI (2000) HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics 52:121
19. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199
20. Jimenez P, Cabrera T, Mendez R, Esparza C, Cozar JM, Tallada M, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2001) A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics 53:606
21. Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, Garcia A, Ruiz-Cabello F, Garrido F (1999) Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91
22. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA, Stern PL (1995) Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405
23. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med, 191:961
24. Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome 6p21 region. Cancer Immunol Immunother 51(7):389
25. Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673
26. Perez B, Benitez R, Fernandez MA, Oliva MR, Soto JL, Serrano S, Lopez Nevot MA, Garrido F (1999) A new beta 2-microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569
27. Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F (2000) Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 55:443
28. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F (2000) Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001
29. Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F, Ruiz-Cabello F (2001) Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 49:621
30. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA (1993) Molecular mechanisms used by tumors to escape immune recognition: immunogenetic therapy and the cell biology of major histocompatibility complex class I. J Immunother 14:182
31. Restifo NP, Ying H, Hwang L, Leitner WW (2000) The promise of nucleic acid vaccines. Gene Ther 7:89
32. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
33. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539
34. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huber C (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2:1427
35. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94:243
36. Soong TW, Hui KM (1991) Regulation of the expression of major histocompatibility complex class I genes in human colorectal cancer. Cancer Detect Prev 15:231
37. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL (1990) HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 2:113
38. Tamiya G, Shiina T, Oka A, Tomizawa M, Ota M, Katsuyama Y, Yoshitome M, Makino S, Kimura M, Inoko H (1999) New polymorphic microsatellite markers in the human MHC class I region. Tissue Antigens 54:221
39. Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M (1999) Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 116:1348